BSEBoard Meeting3d ago · 5 Aug 2026, 04:09 pm
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....
Bal Pharma Ltd · 524824
✦ AI SummaryResults
Bal Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve the Unaudited (Standalone and Consolidated) Financial Statements for the first quarter ended 30th June 2026 and other general business matters.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bal Pharma Ltd - 524824 - Board Meeting Intimation for Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Statements Of The Company For The First Quarter Ended 30Th June 2026 And Other General Business Matters
Attachments (1)
📄pdf
Download →
99e6bb65-f2d6-4f44-b101-4fc492b29f2a.pdf
View document text
To To Date: August 05, 2026
Listing Compliance Department BSE Limited
National Stock Exchange of India Limited, 1st Floor, New Trading Ring,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers,
Bandra Kurla Complex, Bandra (E), Dalal Street,
Mumbai-400051 Mumbai – 400001
Symbol: BALPHARMA Scrip Code: 524824
Sub: Prior Intimation of Board Meeting pursuant to Regulation 29 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of
Directors of Bal Pharma Limited is scheduled to be held on Wednesday, August 12, 2026, inter alia,
to consider and approve the Unaudited Standalone and Consolidated Financial Results of the
Company for the quarter ended June 30, 2026 (Q1/2026-27) and such other matters as may be
considered necessary with the permission of the Chair.
Please takes this intimation on your records
Thanking You.
For Bal Pharma Limited
Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681